Denials Outsourcing vs. In-House Teams: Which Model Gets Better Results?

This question doesn't have a universal answer, but it has a more structured analysis than most hospitals apply when making the decision. The comparison between managing denials internally versus partnering with a specialized external team tends to get framed as a cost question — and cost is worth examining. However, the more revealing question is capability: does the internal model produce the clinical expertise, appeal quality, and lifecycle management that denial complexity now requires? In practice, those two framings often lead to different evaluations and different decisions.

For a broader framework, see denial management healthcare.

What's Changed About the Comparison

Five years ago, denial management was operationally demanding but not fundamentally beyond the reach of well-staffed internal teams. The volume was manageable, the complexity was concentrated in a subset of clinical cases, and the technology gap between internal and external solutions was narrower.

However, the landscape has shifted. Payers have deployed AI-driven denial issuance at scale, driving initial denial rates above 11.8%, per OS Healthcare data. The landscape has shifted considerably.

Clinical denials now require licensed clinical review, payer-specific policy expertise, and multi-level escalation pathways that exceed what standard billing workflows were built to support. As a result, the relevant question for most hospitals is no longer whether internal teams can handle denial management in principle — it's whether they can handle it at the level of complexity that payers are now generating.

The In-House Model: Strengths and Real Constraints

Internal denial management teams have genuine advantages. They have direct access to clinical staff and documentation. They understand the organization's specific payer mix and contract terms. In addition, they have relationships with case managers, coders, and physicians that facilitate appeal development. They also eliminate the coordination friction that comes with any external partnership.

The constraints are structural. Building an internal clinical appeals capability requires specialized talent that is difficult to recruit and expensive to retain — RN reviewers, certified coders, and staff capable of navigating payer-specific policy language across multiple commercial plans and Medicare Advantage contracts. A clinical denial specialist who understands InterQual, MCG, and plan-level Medical Necessity policies is not a typical hire.

Turnover compounds the problem. Complex denials require institutional knowledge about payer behavior that takes months to develop. When experienced staff leave, that knowledge goes with them. As a result, the next hire starts the learning curve over. Organizations that have built strong internal clinical appeals capabilities often find that sustaining them requires constant reinvestment in training, hiring, and technology.

To understand appeal development, see clinical appeals healthcare (Blog #3).

What the Outsourcing Model Provides

A specialized external partner brings the clinical infrastructure that most hospitals would spend years building internally. Effective outsourced denial programs offer:

• Clinical expertise at scale: teams of RN auditors, certified coders, and denial specialists organized by denial type and payer class — not generalists handling everything
• Payer intelligence: accumulated data on payer behavior, overturn rates by payer and denial category, and policy interpretation informed by years of claim-level experience
• Technology: prioritization models, deadline tracking, appeal lifecycle management, and reporting that isn't feasible to build internally at scale
• Contingency alignment: performance-based models that align the partner's economic incentives with the hospital's recovery outcomes

The limitation of outsourcing is the coordination requirement. However, external partners do not have the same direct access to clinical staff and medical records that internal teams have. How well the partner accesses records, communicates findings, and feeds data back into the hospital's systems determines how much friction that coordination creates.

The Metrics That Decide the Comparison

The comparison resolves differently depending on which metrics are weighted. On pure cost per appeal, well-staffed internal teams can be competitive. However, on overturn rate, appeal quality, and lifecycle management, specialized external partners tend to outperform internal teams — often significantly, particularly on clinical denials.

The American Hospital Association documents that hospitals spent $43 billion in 2025 collecting payments already owed, including $18 billion on overturning denials. That administrative burden exists regardless of whether the work is done internally or externally. The question is which model produces higher net recovery per dollar spent.

For high-complexity clinical denials — DRG downgrades, medical necessity appeals, audit defense — the specialist premium is most pronounced. These cases require clinical depth and payer-policy expertise that most internal teams do not maintain at the volume or consistency needed to drive reliable results.

To understand performance outcomes, see denial overturn rates.

A Hybrid Approach

Many health systems have found that the most effective model is neither fully internal nor fully outsourced. Standard administrative denials are handled by internal staff with the tools and workflows to manage them efficiently. High-dollar clinical denials, DRG downgrades, and audit defense cases are routed to specialized partners with clinical expertise and payer-specific appeal experience.

In this model, this means internal teams retain the direct access, payer relationships, and organizational knowledge they are best positioned to use. At the same time, specialized partners handle the clinical denial categories where depth and payer-specific expertise drive the outcome.

To connect upstream improvement, see denial root cause analysis healthcare.

Turning Strategy Into Measurable Results

Revecore's model supports this kind of integration — operating as a clinical extension of hospital revenue cycle teams, handling complex clinical denials through to final resolution while the internal team manages standard administrative work. The result is higher overturn rates and faster cash recovery on the categories where clinical expertise actually changes the outcome.

For organizations looking to improve performance, learn more about denial appeals services.